Browsing by Subject "tacrolimus"
Now showing items 1-10 of 21
-
Análise prospectiva do perfil de segurança do estudo de conversão planejada do regime imunossupressor com base no sirolimo introduzido 3 meses após transplante renal, em comparação com um regime contínuo com base no tacrolimo em pacientes com novo transpl
(Universidade Federal de São Paulo (UNIFESP), 2016-06-30)The safety and tolerability of immunosuppressive regimens derive from complex interactions of factors including known drug-related off-target adverse events, drug doses/concentrations and combinations, demography and time ...
-
Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients
(Dove Medical Press Ltd, 2017)Background: The effects of genetic variants related to the pharmacodynamic mechanisms of immunosuppressive drugs on their therapeutic efficacy and safety have been poorly explored. This study was performed to investigate ...
-
Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation
(Wiley-Blackwell, 2009-08-01)The Symphony study showed that at 1 year posttransplant, a regimen based on daclizumab induction, 2 g mycophenolate mofetil (MMF), low-dose tacrolimus and steroids resulted in better renal function and lower acute rejection ...
-
Circadian and time-dependent variability in tacrolimus pharmacokinetics
(Blackwell Publishing, 2007-04-01)Tacrolimus (TAC) is considered a critical dose drug. the purpose of our study was to investigate circadian and time-dependent changes in TAC pharmacokinetics over the first year after kidney transplantation. Pharmacokinetic ...
-
Efficacy of Sotrastaurin Plus Tacrolimus After de Novo Kidney Transplantation: Randomized, Phase II Trial Results
(Wiley-Blackwell, 2013-07-01)Sotrastaurin, a novel immunosuppressant, blocks early T cell activation through protein kinase C inhibition. Efficacy and safety of sotrastaurin with tacrolimus were assessed in a dose-ranging non-inferiority study in renal ...
-
Estudo prospectivo, controlado, randomizado para avaliar a influência da intervenção farmacêutica na variabilidade intra-individual das concentrações sanguíneas de tacrolimo, nos 3 primeiros meses após o transplante renal
(Universidade Federal de São Paulo (UNIFESP), 2016-06-30)Introduction: Intraindividual variability of tacrolimus concentrations is related to inherent characteristics of this drug, pharmacokinetics and adherence to treatment. Objectives: (1)Evaluate the influence of pharmaceutical ...
-
Gingival Overgrowth Among Patients Medicated With Cyclosporin A and Tacrolimus Undergoing Renal Transplantation: A Prospective Study
(Amer Acad Periodontology, 2011-02-01)Background: the aim of this study is to make a longitudinal evaluation of the incidence and severity of gingival overgrowth (GO) induced by immunosuppressive agents, such as tacrolimus (Tcr) and cyclosporin A (CsA), in the ...
-
The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring
(Blackwell Munksgaard, 2002-08-01)The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. We sought to determine the influence of ethnic miscegenation on tacrolimus pharmacokinetics and trough concentrations ...
-
Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients
(Wiley, 2017)STUDY OBJECTIVE To investigate the influence of single nucleotide polymorphisms (SNPs) in genes encoding metabolizing enzymes (CYP2C8, CYP2J2, and UGT2B7) and transporters (ABCC2 and ABCG2) on dose and dose-adjusted trough ...
-
Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients
(Lippincott Williams & Wilkins, 2016)BackgroundPolymorphisms in genes encoding transport proteins and metabolizing enzymes involved in tacrolimus (TAC) disposition may be important sources of individual variability during treatment.ObjectiveThe aim of this ...
